Sectors

BSX
Boston Scientific Corporation
62.82
900 x 62.64
1100 x 63.18
bid
ask
+
0.82
1.32%
1000 @ 04:00 PM
63.50 +0.68 (1.08%)
Ytd -34.12%
1y -37.21%
61.82
day range
63.20
62.00
52 week range
108.14
Open 62.05 Prev Close 62.00 Low 61.82 High 63.20 Mkt Cap 93.36B
Vol 11.55M Avg Vol 16.17M EPS 1.94 P/E 32.38 Forward P/E 16.07
Beta 0.70 Short Ratio 1.94 Inst. Own 95.00% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 04-22 50-d Avg 75.55 200-d Avg 94.20 1yr Est 101.25
Earning
Date For Estimate Reported Surprise surprise %
2026-04-22 2026-03 0.8 N/A N/A N/A
2026-02-04 2025-12 0.78 0.8 0.02 2.56%
2025-10-22 2025-09 0.71 0.75 0.04 5.63%
2025-07-23 2025-06 0.72 0.75 0.03 4.17%
2025-04-23 2025-03 0.67 0.75 0.08 11.94%
2025-02-05 2024-12 0.65 0.7 0.05 7.69%
Upgrade / Downgrade
Date Firm Action From To
2026-03-30 RBC Capital Upgrade Outperform Outperform
2026-03-30 Raymond James Downgrade Strong Buy Outperform
2026-03-30 Needham Upgrade Buy Buy
2026-03-27 Goldman Sachs Upgrade Buy Buy
2026-03-20 Stifel Upgrade Buy Buy
2026-03-20 Needham Upgrade Buy Buy
Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2025-02-18 BRENNAN DANIEL J Chief Financial Officer 225.81K Conversion of Exercise of derivative security
2026-02-12 BROWN VANCE R General Counsel 54.24K Conversion of Exercise of derivative security
2026-02-12 BUTCHER ARTHUR C Officer 69.15K Conversion of Exercise of derivative security
2024-05-08 DOCKENDORFF CHARLES J Director 62.90K Stock Award(Grant)
2026-02-12 FITZGERALD JOSEPH MICHAEL Officer 219.14K Conversion of Exercise of derivative security
2026-02-12 MAHONEY MICHAEL F Chief Executive Officer 1.79M Conversion of Exercise of derivative security
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 139.69M 8.78B 9.40%
2025-12-30 Blackrock Inc. 135.99M 8.54B 9.15%
2025-12-30 FMR, LLC 97.39M 6.12B 6.55%
2025-12-30 State Street Corporation 65.85M 4.14B 4.43%
2025-12-30 Geode Capital Management, LLC 32.38M 2.03B 2.18%
2025-12-30 Primecap Management Company 31.10M 1.95B 2.09%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 46.59M 2.93B 3.13%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 37.38M 2.35B 2.52%
2025-12-30 VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund 20.64M 1.30B 1.39%
2026-01-30 iShares Trust-iShares Core S&P 500 ETF 19.08M 1.20B 1.28%
2026-02-27 Fidelity Concord Street Trust-Fidelity 500 Index Fund 18.87M 1.19B 1.27%
2026-01-30 SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust 17.80M 1.12B 1.20%
Split
Split Date
2 : 1 2003-11-06
2 : 1 1998-12-01